{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"114.8","value":"215.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent","id":"OG000","title":"Zanubrutinib"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set included all participants who had at least 1 postdose zanubrutinib plasma concentration","reportingStatus":"POSTED","timeFrame":"Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)","title":"Apparent Oral Clearance (CL/F) of Zanubrutinib","type":"SECONDARY","unitOfMeasure":"Liters/hour"}